{"id":"naloxone-intramuscular","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute withdrawal syndrome (agitation, body aches, sweating, tachycardia)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone competitively binds to opioid receptors (mu, delta, and kappa) with higher affinity than opioids, displacing opioids from these receptors and preventing their effects. This rapidly reverses respiratory depression, sedation, and other life-threatening effects of opioid overdose. The intramuscular formulation provides an alternative route of administration for emergency use in opioid overdose situations.","oneSentence":"Naloxone is an opioid antagonist that blocks opioid receptors to rapidly reverse opioid overdose and restore normal breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:36.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal"},{"name":"Emergency treatment of suspected opioid overdose"}]},"trialDetails":[{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT07064564","phase":"PHASE1","title":"iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Akyso Therapeutics, LLC","startDate":"2026-04-01","conditions":"Opioid Use Disorder","enrollment":33},{"nctId":"NCT07269873","phase":"PHASE1","title":"Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol","status":"NOT_YET_RECRUITING","sponsor":"BioCorRx Pharmaceuticals Inc","startDate":"2026-01-13","conditions":"Healthy Adult Male and Female Volunteers","enrollment":30},{"nctId":"NCT07180420","phase":"PHASE1","title":"Proof of Concept (PoC) Evaluation of Naloxone Unique Intramuscular (IM) Injection","status":"COMPLETED","sponsor":"STAT Therapeutics Inc","startDate":"2024-03-24","conditions":"Healthy Volunteer - Complete","enrollment":12},{"nctId":"NCT06374290","phase":"PHASE1","title":"Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-07-16","conditions":"Smoking Cessation","enrollment":2},{"nctId":"NCT06719986","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2022-10-03","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT06633900","phase":"PHASE2, PHASE3","title":"Naltrexone for Overdose Prevention","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-10","conditions":"Overdose Accidental","enrollment":100},{"nctId":"NCT02461927","phase":"PHASE1, PHASE2","title":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-01-01","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":65},{"nctId":"NCT04473950","phase":"PHASE1","title":"The Effect of Chronic Pain on Delay Discounting in Methadone Patients","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-01-08","conditions":"Opioid-use Disorder, Chronic Pain Syndrome","enrollment":10},{"nctId":"NCT04139668","phase":"PHASE2","title":"Vivitrol Treatment for Cannabis Use Disorder","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2021-06-09","conditions":"Cannabis Use Disorder","enrollment":1},{"nctId":"NCT04716881","phase":"PHASE1","title":"Pharmacokinetic Study of Vivitrol in Healthy Participants","status":"COMPLETED","sponsor":"Go Medical Industries Pty Ltd","startDate":"2021-01-25","conditions":"Opioid-use Disorder","enrollment":9},{"nctId":"NCT05808881","phase":"PHASE4","title":"Clinical Outcomes From Nalmefene","status":"WITHDRAWN","sponsor":"Purdue Pharma LP","startDate":"2023-06","conditions":"Opioid Overdose","enrollment":""},{"nctId":"NCT03309449","phase":"NA","title":"A Usability Assessment of Naloxone by Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-08","conditions":"Drug Overdose","enrollment":138},{"nctId":"NCT02324725","phase":"PHASE4","title":"Biomarkers of Injectable Extended Release Naltrexone Treatment","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-10","conditions":"Heroin Dependence, Opioid Dependence","enrollment":32},{"nctId":"NCT05363501","phase":"PHASE1","title":"Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"Pocket Naloxone Corp","startDate":"2021-01-21","conditions":"Opioid Overdose","enrollment":76},{"nctId":"NCT05264493","phase":"PHASE1","title":"Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-10-06","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT02478489","phase":"PHASE4","title":"Alcohol Disorder hOsPital Treatment Trial","status":"COMPLETED","sponsor":"Boston University","startDate":"2016-06","conditions":"Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder","enrollment":248},{"nctId":"NCT01882361","phase":"PHASE2, PHASE3","title":"Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-06","conditions":"Opiate Dependence, Human Immunodeficiency Virus","enrollment":77},{"nctId":"NCT03518021","phase":"PHASE3","title":"Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-05-15","conditions":"Overdose, Drug Abuse","enrollment":286},{"nctId":"NCT02978417","phase":"PHASE4","title":"Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-09-21","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT01246401","phase":"PHASE1, PHASE2","title":"Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-03","conditions":"HIV, AIDS, Opioid Dependence","enrollment":151},{"nctId":"NCT04025671","phase":"NA","title":"A Usability Assessment of Naloxone Administration by Untrained Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2017-08-23","conditions":"Harm Reduction, Opioid-use Disorder, Naloxone","enrollment":208},{"nctId":"NCT01227044","phase":"PHASE2, PHASE3","title":"Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-04","conditions":"Reduction in Heavy Drinking in Patients With HIV","enrollment":51},{"nctId":"NCT01856712","phase":"PHASE3","title":"Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-05","conditions":"Alcohol Dependence","enrollment":54},{"nctId":"NCT03827629","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2017-08-07","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT03827642","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2018-04-23","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT00834080","phase":"PHASE3","title":"ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2009-03","conditions":"Opiate Dependence","enrollment":38},{"nctId":"NCT02307721","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-12","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT03658330","phase":"PHASE2","title":"Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Connecticut Healthcare System","startDate":"2016-05","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":5},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT03386591","phase":"PHASE1","title":"Comparison of Naloxone Pharmacokinetics","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2018-01-03","conditions":"Opioid-use Disorder","enrollment":30},{"nctId":"NCT01389167","phase":"PHASE3","title":"Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-09","conditions":"Opiate Dependence","enrollment":320},{"nctId":"NCT00577408","phase":"PHASE3","title":"Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opiate Dependence, Heroin Dependence","enrollment":60},{"nctId":"NCT00156923","phase":"PHASE3","title":"ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2003-10","conditions":"Alcoholism","enrollment":108},{"nctId":"NCT01218958","phase":"PHASE3","title":"ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-02","conditions":"Alcoholism","enrollment":624},{"nctId":"NCT00511836","phase":"PHASE4","title":"ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2007-07","conditions":"Alcohol Dependence","enrollment":31},{"nctId":"NCT00678418","phase":"PHASE3","title":"ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2008-06","conditions":"Opiate Dependence","enrollment":250},{"nctId":"NCT02598856","phase":"PHASE1","title":"Bioavailability of Nasal Naloxone and Injected Naloxone Compared","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-03","conditions":"Drug Overdose","enrollment":22},{"nctId":"NCT02572089","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2014-10","conditions":"Drug Overdose, Opioid-Related Disorders","enrollment":30},{"nctId":"NCT02750748","phase":"PHASE1","title":"Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2016-07","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT01218984","phase":"PHASE2","title":"ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2002-03","conditions":"Opiate Dependence","enrollment":27},{"nctId":"NCT02733822","phase":"PHASE1","title":"Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study","status":"UNKNOWN","sponsor":"King's College London","startDate":"2016-06","conditions":"Drug Overdose, Opioid-Related Disorders","enrollment":4},{"nctId":"NCT01449565","phase":"PHASE2","title":"Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)","status":"COMPLETED","sponsor":"San Francisco Department of Public Health","startDate":"2012-09","conditions":"Amphetamine-Related Disorders","enrollment":100},{"nctId":"NCT01563718","phase":"PHASE4","title":"Pre-Release VIVITROL for Opioid Dependent Inmates","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2012-03","conditions":"Substance-Related Disorders","enrollment":26},{"nctId":"NCT02138396","phase":"NA","title":"Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2014-01","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT01912573","phase":"PHASE4","title":"Nasal Naloxone for Narcotic Overdose","status":"UNKNOWN","sponsor":"Judith Feinberg","startDate":"2013-09","conditions":"Drug Overdose","enrollment":236},{"nctId":"NCT00984360","phase":"PHASE2","title":"Study of Naltrexone for Methamphetamine Addiction","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2009-09","conditions":"Methamphetamine Dependence","enrollment":22},{"nctId":"NCT00501631","phase":"PHASE3","title":"ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2007-07","conditions":"Alcohol Dependence","enrollment":300},{"nctId":"NCT00890942","phase":"NA","title":"Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2009-05","conditions":"Morphine Adverse Reaction","enrollment":60},{"nctId":"NCT01218997","phase":"PHASE3","title":"ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2003-08","conditions":"Alcoholism","enrollment":436},{"nctId":"NCT00156936","phase":"PHASE3","title":"ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])","status":"TERMINATED","sponsor":"Alkermes, Inc.","startDate":"2004-08","conditions":"Alcoholism, Opiate Dependence","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":333,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Naloxone, intramuscular","genericName":"Naloxone, intramuscular","companyName":"Norwegian University of Science and Technology","companyId":"norwegian-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone is an opioid antagonist used to counteract opioid overdose, and it is also studied in clinical trials for conditions such as opioid dependence and methamphetamine dependence. Naloxone is administered intramuscularly to reverse opioid overdose, but its exact mechanism of action is not specified in the provided facts, although it is known to bind to opioid receptors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}